GHS/USC FACULTY
CURRICULUM VITAE FORMAT
Name: MARK ALLEN O’ROURKE, M.D.
Updated: 9/15/2015
Birthdate: June 30, 1952
Social Security #: 523-62-0500
Home Address: 408 McDaniel Avenue, Greenville, SC 29601
Phone: (864) 233-6339, cell (864) 979-1304
Office Address: Greenville Health System Cancer Institute
65 International Drive, Greenville, SC 29615
Phone: (864) 987-7000
Fax: (864) 987-1254
Email: morourke@ghs.org
Race: Caucasion
Gender: M Marital Status: M
Spouse Name: Rita
Citizenship and/or Visa Information: U.S. citizen by birth
Education (Beginning with Baccalaureate Degree):
Institution/Location:
Years
Degree/Date:
Stanford University
1970-74
B.S./1974
UCLA School of Medicine
1978-82
M.D.
Internship:
Duke University Medical Center
1982-83
Residency:
Duke University Medical Center
1983-84
Fellowship: Duke University Medical Center
1984-87
Fellowship: Duke University Medical Center
1985-87
Field of Study:
Chemistry
Medicine
Internal Medicine
Internal Medicine
Hematology/Oncology
Geriatrics
Specialty/Board Certification:
American Board of Internal Medicine,
Board Certified, Oncology
Board Certified, Geriatrics
Board Certified, Hospice and Palliative Medicine
Board Certified, Hospice and Palliative Medicine
#104166
#104166
#104166
#5000054
#104166
Licensure:
North Carolina Medical License (inactive)
South Carolina Medical License (active)
DEA number:
South Carolina Drug Control number:
BCLS certified
#27626
12/06/1983
#14771
02/20/1990
AO 1650440
20-P331
2-18-2011
Military Service:
Navy R.O.T.C.
U.S. Navy, Lieutenant, Honorable Discharge
Instructor, Naval Nuclear Power School
09/11/1985
11/10/1987
04/20/1988
01/01/2006
02/05/2009
1970-74
1974-78
Faculty Appointments (Begin with initial appointment:
Years
Rank
Institution
1990 to present
1993-94
Department
Volunteer Faculty, Department Internal Medicine
Greenville Hospital System (GHS), Greenville, SC
Golden Apple Award
2006 to present
GHS Clinical Assistant Professor of Hematology/Oncology
Department of Internal Medicine
University of South Carolina School of Medicine Greenville
2012 to present
Medical Director, Center for Integrative Oncology & Survivorship
Greenville Health System University Medical Center
Author of Survive and Thrive blog, at blog.ghs.org
Administrative Appointments:
Years
Position
Institution
Department
1990-96
member
Institutional Review Committee, GHS
1994-95
chairman Institutional Review Committee, Greenville Hospital System
1994-95
Medical Director for Research, Oncology, GHS
1987-present
NCI Community Clinical Oncology Program (CCOP)
1987-1990
Investigator, Southeastern Cancer Control Consortium CCOP
1995-1996
Principle Investigator, Greenville, SC CCOP
1996 to 2014
Investigator, Greenville, SC CCOP
2014 to present
Investigator, National Community Oncology Research Program
(NCORP) of the Carolinas
NCI INVESTIGATOR NUMBER: #16151, SWOG Roster ID 13915
Drug Management and Authorization Section, IDB, CTEP, Division of Cancer Treatment,
NCI, Executive Plaza North, Room 707-A, Bethesda, Maryland 20892 (301) 496-5725
Hospital Appointments/Privileges:
Years
Active/Inactive
Institution
1990 to present
Active
Greenville Hospital System
1990 to present
Courtesy
St. Francis Health System
1995 to present
Consulting
Oconee Medical Center
Other Experience:
Years
1985-1987
1986-1987
1991-1995
1996-1998
1997
Position
Institution
Department
Cancer Pain Study Committee, Durham VA Medical Center
Medical Director, Triangle Hospice, Durham, NC
Medical Director, St. Francis Hospice, Greenville, SC
Medical Director, Interim Hospice, Greenville, SC
South Carolina Pain Initiative, Member
April 5-12 & November 9-15, 2005
Faculty Scholar, The Program in Palliative Care Education and Practice
(PCEP), Harvard Medical School Center for Palliative Care, Boston, MA
October 12-14, 2005
Participant, Palliative Care Leadership Centers Site Visit
Program, Hospice of the Bluegrass, Lexington, KY
Membership in professional/scientific societies (include offices held):
Southwest Oncology Group (National Cancer Institute) 1990 to the present
Cancer Control and Cancer Survivorship Committees, 2012 to the present
Coalition for the Care of the Seriously Ill, Steering Committee, 2010 to the present
Co-principle investigator, Pilot Study for the Implementation of Physician Orders
for Scope of Therapy (POST) in South Carolina, initiated fall 2012
National Cancer Institute Symptom Management & Health-Related Quality of Life
Steering Committee (SxQOL SC), 2015 to 2018
National and State Societies
1987-present American Medical Association, member
1987-present American Society for Clinical Oncology (ASCO), member
2012-2015
ASCO Ethics Committee member
1990-present South Carolina Medical Association, Member
1997-1999
Oncology Representative, Interdisciplinary Council
2009-present SCMA Bioethics Committee, member
1995-present South Carolina Oncology Society, Member
1997-1998
Secretary
2000-present Christian Medical Association
2002-present Catholic Medical Association
2005-present American Academy of Hospice and Palliative Medicine, member
Local Societies
1990-present Greenville County Medical Society, Member
2002-05
Legislative Representative
Secretary
Treasurer
President
Editorial Positions:
Extramural Grants/award amount (current or past):
As Principal Investigator (% time)
As Co-Investigator (% time)
Intramural Grants/amount of awards:
Greenville Health System Transformative Research Seed Grant, Principle Investigator
2014 Use of Heart Rate Variability (HRV) Biofeedback for Cancer Survivors
2015 Mindfulness Intervention for Cancer Survivors
Awards, Honors, Membership in Honorary Societies:
November 2005
Order of St. Luke Award, first annual,
for physician compassionate care and service,
Bon Secours St. Francis Health System,
Greenville, SC
April 28, 2012
South Carolina Medical Association
2012 Physician of the Year Award for Community Service
Academic Committee Activities (past 5 years):
University
College
Department
Division
Member, Admissions Committee
University of South Carolina School of Medicine-Greenville
September 2011 to 2013
Major Teaching Responsibilities (Current):
Volunteer faculty, hematology & oncology: medical students and postgraduate
Undergraduate Medical Education
Lecturer, Medical Ethics, 2012-present
Lecturer, Oncology, 2014-present
Graduate Medical Education
Graduate Studies Education
Continuing Medical Education
Major Clinical Interests and Responsibilities:
2012 to present
Medical Director, Center for Integrative Oncology & Survivorship
Greenville Health System University Medical Center
Author of Survive and Thrive blog, at blog.ghs.org
2013 to present
Institute for Translational Oncology and Research (ITOR)
Clinical Research Unit: Investigator
Practice of hematology and medical oncology
Gastrointestinal Malignancy Multidisciplinary Clinic
Palliative Care: communication, consent and decision-making
Integrative Oncology, Cancer Survivorship
Co-principle Investigator, Survey to Assess Cancer Survivor Nutrition Needs and
Preferences, initiated summer 2014
Principle Investigator, Greenville Health System Cancer Institute Cancer Survivor
Registry, initiated spring 2013
Co-principle investigator, Pilot Study for the Implementation of Physician Orders for
Scope of Therapy (POST) in South Carolina, initiated fall 2012
Lectures and Presentations: during the last 3 years – Identify the name and location of
the meeting/conference. List presentations under the following headings:
Invited lectures and presentations
Cancer Survivorship
Greenville Health System, OB-GYN Grand Rounds
April 20, 2015
POST Pilot Project
Diocese of Charleston
Family and Respect Life Conference
Columbia, SC
August 17, 2013
Cancer Survivorship in 2013
Grand Rounds, Department of Internal Medicine, Greenville Health System
Greenville, SC
March 19, 2013
POST Pilot Project
Catholic Medical Association
Blessed Clemens von Galen Guild (South Carolina)
Charleston , SC
October 6, 2012
POST is Coming to South Carolina
The Carolinas Center for Hospice and End-of-Life Care
2012 Hospice and Palliative Care Annual Conference
Greenville, SC
September 25, 2012
South Carolina Coalition for Care of the Seriously Ill (CSI)
Uniform Processes to Improve Consent, Communication, and Decision Making in South
Carolina Hospitals
South Carolina Hospital Association
Fifth Annual Patient Safety Symposium
Columbia, SC
April 26, 2012
Consent, Communication and Decision-Making for the Seriously Ill in South Carolina
Hospitals
South Carolina Medical Association
Sixth Annual Health Law Symposium
Columbia, SC
February 17, 2012
Communication Review of Systems, An Aid for Caring for the Seriously Ill
South Carolina Healthcare Ethics Network Annual Meeting
Summit on Care of the Seriously Ill
Columbia, SC
October 12, 2011
Communication Review of Systems
SCMA Annual Meeting, Bioethics Scientific Session
Ethical Issues of Informed Consent in the 21st Century
Greenville, SC
April 30, 2011
Communication Review of Symptoms
South Carolina Medical Association Ethics Committee Annual Retreat
Hilton Head, SC
February 4, 2011
Communication Review of Systems
Internal Medicine Grand Rounds
Greenville Hospital System University Medical Center
November 5, 2010
Metabolic Effects of Chemotherapy in Surgical Patients
Educational Conference, Department of Surgery
Greenville Hospital System University Medical Center
September 8, 2010
Cord Blood Stem Cell Therapy in 2010
Fertility Preservation in Cancer Care in 2010
American Society of FertilityCare Professionals, 29th Annual Meeting
Greenville, South Carolina
July 24, 2010
Interdisciplinary Management of GI Malignancy: Colorectal Cancer, GIST,
Neuroendocrine Tumors, and Pancreas Cancer,
Grand Rounds, Department of Surgery,
Greenville Health System University Medical Center,
May 21, 2010
Abortion and Breast Cancer: What is the Evidence?
St. Joseph Catholic Church, Columbia, South Carolina
April 27, 2010
End-of-Life Issues: When Should Palliative Care Begin?
54th Annual Greenville Postgraduate Seminar: A Primary Care Update,
April 16, 2010
End-of-Life Care Planning, The Challenge for the Medical Profession
South Carolina Medical Association Ethics Committee Annual Retreat,
February 5, 2010
Human Embryonic Stem Cell Ethics and Politics in 2009
North Carolina Catholic Medical Association
September 19, 2009
Lung Cancer Staging
South Carolina Cancer Registrars Association Fall Meeting
Greenville, South Carolina
August 5, 2009
Human Embryonic Stem Cell Ethics and Politics 2007
First Monday, Greenville County GOP
July 9, 2007
Stem Cell Ethics 2006
Christ Our Risen Savior Catholic Church
Spartanburg, SC
October 30, 2006
Delivering Bad News
Greenville Chapter
Christian Medical Association, Greenville, SC Chapter
October 19, 2006
Respect for Life in End of Life Care
Diocese of Charleston, St. Mary’s Church, Greenville, South Carolina
October 20, 2005
Geriatric Oncology Course, Clemson University School of Nursing, Greenville, SC
Palliative Care in the Last Days of Life, May 2005
Cancer in the Elderly, March 2004
Stem Cells, Medicine, and Human Rights
Diocese of Charleston Pro-Life Conference
Aiken, SC
May 14, 2005
Stem Cells, Medicine, and Human Rights
Furman University Faculty for Life Lecture, Furman University
Greenville, SC
March 1, 2005
Leukemia & Lymphoma Society Patient Education Programs, St, Francis Hospital,
Greenville, SC, February 2002, February 2003, February 2004, & June 2005
Embryonic Stem Cell Research and Cloning 2004: The Defining Life Issues of Our Time
Diocese of Charleston, St. Mary’s Church
Greenville, South Carolina
October 14, 2004
Embryonic Stem Cell Research and Cloning 2004: Still a Big Problem for Human Life
Christian Medical and Dental Association, Greenville Chapter
May 18, 200
Medical Grand Rounds, Greenville Memorial Medical Center, Greenville, SC
October 2005 Palliative Care & Hospice in 2005
October 2003 Palliative Care
August 1999 End of Life Care
June 10, 1998 End of Life Care
End of Life Care
South Carolina Respect Life Conference, Columbia, SC, August 23, 2003
Embryonic Stem Cell Research and Cloning
Undergraduate Community Affairs Program, Furman University, February 2, 2003
Breast Cancer: Treatment and Prevention
Blue Cross & Blue Shield of South Carolina employees training, January 17, 2002
Breast Cancer: Treatment and Prevention
St. Francis Hospital Community Education Series, June 21, 2001
Health Disparities and Barriers in South Carolina
President’s Cancer Panel, Regional Meeting, Nashville, TN, November 16, 2000
Medicare Part B Coverage of Injectable Drugs
Town Hall Meeting Presentation, Health Care Financing Administration (HCFA)
May 17, 2000
Baltimore, Maryland
July 25, 2000
Chicago, Illinois
Navelbine in the Treatment of Lung Cancer
Glaxo Wellcome Meeting, Pinehurst, NC, March 7, 1998
Historical Review of Randomized, Phase II Trials with Navelbine (Vinorelbine) in NonSmall Cell Lung Cancer
Glaxo Wellcome Investigators Meeting, McLean Virginia, June 15, 1996
P70-01: A Randomized Study Comparing IV Navelbine and IV Alkeran for the Treatment
of Patients with Advanced Breast Cancer Refractory to Anthracycline Therapy
Glaxo Wellcome Investigators Meeting, Marco Island Florida, February 2, 1996
Advisory Board, Refractory Advanced Breast Cancer
Member and Presenter, Glaxo Wellcome, New York, NY, September 27, 1995
Update: Navelbine in Metastatic Breast Cancer
Wellcome Oncology Investigators Meeting, at the annual meeting of the American
Society of Clinical Oncology (ASCO), Los Angeles, CA, May 21, 1995
Navelbine: A New Chemotherapy Drug for Lung Cancer and Other Cancers
Seminar, Division of Hematology and Oncology, Medical University of South Carolina,
Charleston, SC, April 21, 1995
Navelbine for Non-Small Cell Cancer
Consultant and Presenter, Representative Training, Glaxo Wellcome, Research Triangle
Park, NC, January 9, 1995 and August 20, 1995
Navelbine Treatment IND Audio Teleconference, Moderator
National Audio conference, Research Triangle Park, NC, June 22, 1994
Navelbine Indications for Breast Cancer: Overview
Presentation to Oncology Drug Advisory Committee, U.S. Food and Drug Administration,
Bethesda, MD, June 7, 1994
Navelbine
New Technology Symposium, Association of Community Cancer Centers, 20th Annual
National Meeting, Washington, DC, March 26, 1994
Randomized Study of IV Navelbine vs. 5FU + Leucovorin (P70-02)
Wellcome Oncology Investigators Meeting, Dallas, TX, November 13, 1993
Multiple Myeloma
Data Mangers Symposium, Southwestern Oncology Group, April 23, 1993
Lung Cancer
Glaxo Representative Training, Research Triangle Park, NC, December 6, 1992
Effective Social Work Practice and Management in Adult Services
Core Curriculum in Geriatrics, Multidisciplinary Teams in Geriatrics
UNC-Chapel Hill School of Social Work, North Carolina Health Education Program
Wake AHEC 01/29/87
Mountain AHEC
05/15/87
Eastern AHEC
10/29/87
Northwest AHEC
02/11/88
Fayetteville AHEC
05/06/88
Charlotte AHEC
08/04/88
Submitted presentations (e.g., abstract or paper presentations)
Leighton,P., Franco,R., O’Rourke,M., Otto, R. “A Process Improvement Measure:
Development of a Patient Satisfaction Tool in a Survivorship Program”, SC Nursing
Excellence Conference, Columbia, SC. April 11,2014.
Perkins,l., Franco, R., McCormick,D., Savage, K., Leighton, P., Hoopes, S., Susko, K., Obi,
F., O’Rourke, Morrow, Denham, N., “A Multi-disciplinary Survivorship Care Plan Clinic
Model”, SC Nursing Excellence Conference, Columbia, SC. April 11,2014.
Physician order for scope of treatment (POST) in South Carolina (SC).
Mark Allen O'Rourke, Matthew F. Hudson, Janet B. Craig, John C. Ropp, and Karen
Reeves
ASCO Quality Care Symposium, San Diego, CA 12-01-2012
ASCO MEETING ABSTRACTS Dec 4, 2012:21
Supervised exercise for cancer survivors during and after active therapy.
Mark Allen O'Rourke, Regina A Franco, Dawn W. Blackhurst, Jennifer C. Trilk, Matthew F.
Hudson, and William Larry Gluck
ASCO Quality Care Symposium, San Diego, CA 12-01-2012
ASCO MEETING ABSTRACTS Dec 4, 2012:121
Extramural Professional Activities
1988-1990
Bioethics Resource Group, Member
118 Colonial Avenue, Charlotte, NC 28207
1988-1990
Nursing Home Ethics Group Subcommittee Member
1997-2005
South Carolina Department of Health and Environmental Control (DHEC)
Cancer Control Advisory Committee, member
2002 Vice Chairman
1998-2002
South Carolina Medicare Part B Carrier Advisory Committee
Palmetto GBA, Blue Cross and Blue Shield of South Carolina
Columbia, South Carolina
2002 Vice Chairman
2003-2005
South Carolina Department of Health & Human Services
Pharmacy & Therapeutics Committee, Member
2014-present South Carolina Governor’s Prescription Drug Abuse Prevention Council
Community Service:
1992-96
Upstate SC Chapter Board, Alzheimer’s Association, Member
1993 to 2003
American Cancer Society, Southeast Division, Inc.
1993-94
President, Greenville County Chapter
2002-2003
Relay Community Ambassador
2002
Celebration on the Hill, Washington, D.C.
1995 to present
Greenville Free Clinic, Greenville, SC, volunteer
1997-present
Insights, Greenville Chapter, South Carolina Citizens for Life
Chairman, Community Advisory Board
1999-2003
Hospice of the Foothills Foundation Board, member
Seneca, South Carolina
2002-2004
Bon Secours St. Francis Health System
Foundation Board, Member
2002 to present
South Carolina Cancer Alliance, Founding Member
2002-2005
Policy and Advocacy Task Force, Vice Chairman
2003-2010
Hospice House of Greenville Board, Founding Member
2003-2010
Chair of the Board
Publications: Number and list in chronological order publications under the following
headings in the order shown.
Peer Reviewed Journal Articles: Published or accepted for publication in final form
Ligibel JA1, Alfano CM2, Hershman D2, Ballard RM2, Bruinooge SS2, Courneya KS2,
Daniels EC2, Demark-Wahnefried W2, Frank ES2, Goodwin PJ2, Irwin ML2, Levit LA2,
McCaskill-Stevens W2, Minasian LM2, O'Rourke MA2, Pierce JP2, Stein KD2, Thomson
CA2, Hudis CA2. Recommendations for Obesity Clinical Trials in Cancer Survivors:
American Society of Clinical Oncology Statement. J Clin Oncol. 2015 Aug 31. pii:
JCO.2015.63.1440. [Epub ahead of print]
Smerage, JB …O’Rourke, MA, et al. Circulating Tumor Cells and Response to
Chemotherapy in Metastatic Breast Cancer: SWOG 0500. J Clin Oncol 2014; 32,
published online July 2, 2014
O’Rourke, Mark. Communication, Consent and Medical Decision-Making for Seriously Ill
Inpatients. Journal of the South Carolina Medical Association. 2012; 108:36-37
D. Niedzwiecki, M. M. Bertagnolli, R. S. Warren, C. C. Compton, N. E. Kemeny, A. B.
Benson III, S. G. Eckhardt, S. Alberts, G. N. Porjosh, D. J. Kerr, A. Fields, P. Rougier, J. M.
Pipas, J. H. Schwartz, J. Atkins, M. O'Rourke, M. C. Perry, R. M. Goldberg, R. J. Mayer,
and T. A. Colacchio. Documenting the Natural History of Patients With Resected Stage II
Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With
Edrecolomab or Observation: Results From CALGB 9581. JCO 2011 29: 3146-3152
Reynolds C, Obasaju C, Schell MJ, Li X, Boulware D, Caton JR, DeMarco LC, O’Rourke MA,
Wright GS, Boehm KA, Asmar L, Bromund J, Bepler G. Randomized Phase III Trial of
Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for
Response Prediction in Non-Small-Cell Lung Cancer. J Clin Oncol. 2009 Dec
1;27(34):5808-5815 [Epub 2009 Nov2]
Carter DL, Asmar L, Barrera D, Caracandas J, Dakhil JS, McCracken D, O'Rourke MA,
Rosenberg RK, Boehm KA, Ilegbodu D, Reid RL.
HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/18473121"
Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated
hyperfractionated radiotherapy for treatment of locally advanced head and neck
carcinoma.
Invest New Drugs. 2008 Oct;26(5):473-81. Epub 2008 May 13
Berry W, Elkordy M, O'Rourke M, Khan M, Asmar L.
HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/17364554"
Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma
of unknown primary origin: a reasonable regimen for the community-based clinic?
Cancer Invest. 2007 Feb;25(1):27-31. PMID: 17364554
Haller, DG,…,O’Rourke MA, et al.: Phase III Study of Fluorouracil, Leucovorin, and
Levamisole in High-Risk Satge II and III Colon Cancer: Final Report of Intergroup 0089. J
Clin Oncol 2005; Dec 1;23(34) 8671-8. PMID: 16314627
D. L. Carter, …M. A. O'Rourke, et al: A randomized phase III trial of combined paclitaxel,
carboplatin, and radiation therapy followed by either weekly paclitaxel or observation in
patients with stage III non-small cell lung cancer. J Clin Oncol 2004; ASCO Annual
Meeting Proceedings (Post-Meeting Edition).(⁖ ol 22, No 14S (July 15 Supplement),
2004: 7076Ê
Loesch D,É,OÕRourke MA, et al.: Phase II Multicenter Trial of a Weekly Paclitaxel and
Carboplatin Regimen in Patients with Advanced Breast Cancer. J Clin Oncol 2002;
20:3857-3864.Ê
O’Rourke MA, et al.: Phase II Multicenter Trial of a Weekly Paclitaxel and Carboplatin
Regimen in Patients with Advanced Breast Cancer. J Clin Oncol 2002; 20:3857-3864.
Ê
O’Rourke MA, et al.: Mulitcenter Phase II Study to Evaluate a 28-Day Regimen of Oral
Fluorpuracil Plus Eniluracil in the Treatment in the Treatment of Patients with Previously
Untreated Metastatic Colorectal Cancer. J Clin Oncol. 2000 Aug;18(15):2894-901.
O’Rourke MA, Loesch D, et al.: Efficacy and tolerability of a weekly Taxol (T) plus
Carboplatin (C) regimen in patients <65 years versus 3 65 years with advanced breast
cancer (ABC). Proceedings American Society of Clinical Oncology 2002; 21: 39b, #1967
Walls J, O’Rourke MA, et al.: First-Line Therapy of Taxotere (T) and Navelbine (N) in
patients with advanced Non-Small Cell Lung Cancer (NSCLC): a Phase II Study.
Proceedings American Society of Clinical Oncology 2000; 19 #2158
Shepard FA, O’Rourke MA, et al.: Prospective Randomized Trial of Docetaxel versus Best
Supportive Care in Patients with Non-Small-Cell Lung Cancer Previously Treated with
Platinum - Based Chemotherapy. J Clin Oncol 2000; 18 (10): 2095-2103
Sridhar M,…, O’Rourke MA, et al: Multicenter Phase II Study to Evaluate a 28-Day
Regimen of Oral Fluorouracil Plus Eniluracil in the Treatment of Patients with Previously
Untreated Metastatic colorectal Cancer. J Clin Oncol 2000; 18 (15): 2894-2901
Kraut E,…,O’Rourke MA, et al: A Phase II Study of 9-Amino camptothecan in Patients
with Refractory Breast Cancer. Cancer Investigation 2000; 18 (1): 28-31
Schilsky RL,…, O’Rourke MA, et al: A Multicenter Phase II Study of a five-day regimen of
oral 5-fluorouracil plus Eniluracil with or without Leucovorin in patients with Metastatic
colorectal cancer. Ann Oncol 2000; 11 (4): 415-20
O’Rourke MA, Garfield D, et al: Phase II Trial of Taxotere (T) and Navelbine (N) as firstLine Therapy in Patients (pts) with advanced non-small cell lung cancer (ANSCLC)
Proceedings American Society of Clinical Oncology 1999; 18 #1999
Dancy J,…O’Rourke MA, et al: Quality of Life (QOL) Assessment in a randomized study of
Taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC)
patients (pts) previously treated with platinum based chemotherapy. Proceedings
American Society of Clinical Oncology 1999; 18 #1896
Sheperd F,…O’Rourke MA, et al: Randomized Study of Taxotere (TAX) versus best
supportive care (BSC) in non-small cell lung cancer (NSCLC) in patients previously
treated with platinum-based chemotherapy. Proceedings American Society of Clinical
Oncology 1999;18 #1784
Burger RA,…O’Rourke MA, et al: Phase II trial of vinorelbine in recurrent and progressive
epithelial ovarian cancer. Gynecol Oncology 1999; 72 (2): 148-53
Vogel C,…O’Rourke MA, et al: Vinorelbine as first line chemotherapy for advanced
breast cancer in women 60 years of age or older. Annals of Oncology 1999; 10: 397-402.
Field-Jones S,…O’Rourke MA, et al: Improvements in clinical benefit with vinorelbine in
the treatment of hormone-refractory prostate cancer. A phase II Trial. Annals of
Oncology 1999;10: 1307-1310
Mani S,…O’Rourke MA, et al: A Phase II Open-Label study to evaluate a 28-day regimen
of oral 5-fluoroural (5-FU) plus 776C85 for the treatment of patients with previously
untreated Metastatic colorectal cancer. Proceedings American Society of Clinical
Oncology 1998;17 #1083
O’Rourke, MA, Klassy, J.A., et al. An evaluation of a two drug combination of Navelbine
and Cisplatinum as Neoadjuvant Therapy for patients presenting with inoperable Stage
III A or B Non-Small Cell Lung Cancer (NSCL). Proceedings American Society Clinical
Oncology 1997: 16 (submitted)
Schilsky, R., O’Rourke, MA, et al. A Phase II study of a five day regimen of Oral 5Fluorouracil (5-FU) plus GW776 (776C85) with or without Leucovorin (LV) in patients
with Metastatic Colorectal Cancer. Proceedings American Society Clinical Oncology
1997: 16 (submitted)
O’Rourke MA, Shalabi A, Webb S: Methadone for Treatment of Cancer Pain. JAMA
1996; 275 (7): 519 Letter.
Garst M, O’Rourke MA, et al: Vinorelbine (NVB) and Carboplatinum for the Treatment
of Patients with Advanced Non-Small Cell Lung Cancer (NSVLC): A Phase II Response,
Toxicity, and Survival Study. Proceedings American Society Clinical Oncology 1996; 15:
70
Smalley R, O’Rourke MA, et al: An Evaluation of a Two Drug Combination of Navelbine
and Cisplatinum as Neoadjuvant Therapy for Patients Presenting with Inoperable Stage
III A or B Non Small Cell Lung Cancer CNSLC. Proceedings American Society Clinical
Oncology 1996; 15: 1203. 30 -32.
Crawford J, O’Rourke, MA, et al: Randomized Trial of Vinorelbine compared with
Fluorouracil plus Leucovorin in patients with Stage IV Non-Small Cell Lung Cancer. J Clin
Oncol. 1996 14 (ID): 2774-2784.
Crawford J, O’Rourke MA, et al: Sequential Trials of Vinorelbine (Navelbine) with
Carboplatin in Patients with Advanced Non Small Cell Lung Cancer. Proceedings
American Society Clinical Oncology 1995; 14:1162.
Jones S, O’Rourke MA, et al: A Randomized Comparison of Navelbine (Vinorelbine) and
Alkeran (Melphalan) in Anthracycline-Refractory Advanced Breast Cancer. J Clin Oncol
1995; 13:2567-2574.
Williamson SK, O’Rourke MA, et al: Phase II Evaluation of Didemnin B in Hormonally
Refractory Metastatic Prostate Cancer. Investigational New Drugs 1995; 13: 167-170.
Jones S, O’Rourke MA, et al.: A Multicenter Randomized Trial of IV Navelbine vs. IV
Alkeran in Patients with Anthracycline-Refractory Advanced Breast Cancer. Proceedings
American Society Clinical Oncology 1994; 13: 216.
Crawford J, O’Rourke MA, et al.: A Phase I/II Trail of Dose Escalation of Navelbine
Patients with Advanced Non Small Cell Lung Cancer (NSLC). Proceedings American
Society Clinical Oncology 1994; 13: 1176.
Muss HB, O’Rourke MA, et al.: Tamoxifen versus High Dose Oral Medroxyprogesterone
with Metastatic Breast Cancer. A Piedmont Oncology Association (POA) Study. J Clin
Oncol 1994; 12 (8): 1630-1638.
Hazuka MB, O’Rourke MA, et al.: Daily Low-Dose Cisplatinum Plus Concurrent HighDose Thoracic Irradiation in Locally Advanced Unresectable Non-Small Cell Lung
Cancer: Results of a Phase II Southwest Oncology Group Study. J Clin Oncol 1994; 12
(9): 1814-1820.
Crawford J,…O’Rourke MA, et al: Vinorelbine (Navelbine)/ Carboplatin combination
therapy. Dose intensification with granulocyte colony-stimulating factor. Semin
Oncology 1994; 21 (5 suppl 10): 738
Wilding G, O’Rourke MA, et al.: Phase II Trial of Navelbine In Metastatic Renal
Cancer. Proceedings American Society Clinical Oncology 1993; 12: 798.
O’Rourke MA, et al.: Survival Advantage For Patients with Stage IV NSCLC treated with
Single Agent Navelbine in a Randomized Controlled Trial. Proceedings American Society
of Clinical Oncology 1993; 12: 1148.
Cruz J,..., O’Rourke MA, et al.: Menogaril in the Treatment of Relapsed Multiple
Myeloma. Investigational New Drugs 10: 35-37, 1992.
Muss H, O’Rourke MA, et al.: Tamoxifen (CT) Versus High-Dose Oral
Medroxyprogesterone Acetate (MPA) As First Line Endocrine Therapy (RX) for
Metastatic Breast Cancer (MBC): A Randomized Trial of the Piedmont Oncology
Association. Proceedings American Society Clinical Oncology 1991;10:30.
Combs MR,…O’Rourke MA, et al: An acute-anti-M causing hemolysis in vitro.
Transfusion 1991; 31 (8) 756-8
Atkins JN,…O’Rourke MA, et al: High-Dose 24-hour infusion of 5-fluorouracil in
Metastatic prostate cancer. A Phase II trial of the Piedmont Oncology Association.
American Journal Clinical Oncology 1991;14 (6): 526-9
Atkins JN, O’Rourke MA: High-dose 5-Fluorouracil (5-FU) for Hormone Refractory
Advanced Prostate Cancer (APC): A Phase II Trial of the Piedmont Oncology
Association. Proceedings American Society Clinical Oncology 1990; 9: 554.
Powell BL, O’Rourke MA: Combination Carboplatin (CBDCA) and Cisplatin (CDDP) for
advanced Squamous Cell Carcinoma Of the Head and Neck (SCHN). Proceedings
American Society Clinical Oncology 1990; 9: 693.
O’Rourke MA, Combs MR, Telen MJ: An Example of In Vitro Hemolytic Auto-AntiM. Transfusion 1989; 29: 185, #S50.
Crawford J, O’Rourke MA, Cohen HJ: Age Factors in the Management of Lung Cancer. In
Yancik R. and Yates J.W. (Eds.): Cancer in the Elderly Approaches to Diagnosis and
Treatment. New York, Springer Publishing Co., 1989; 177-203.
Crawford J, O’Rourke MA, Robertson J: Age Factors in Lung Cancer. Proceedings
American Society Clinical Oncology 1988; 7: 215.
O’Rourke MA, Laszlo J: Age Trends in Lung Cancer Stage and Histology: Implications for
Screening (Abstract, American Geriatrics Society, November 19, 1987).
O’Rourke MA, Feussner Jr. FP, Laszlo J: Age Trends of Lung Cancer Stage at
Diagnosis: Implications for Lung Cancer Screening of the Elderly. JAMA 1987;258:921926.
O’Rourke MA: Nursing Home Placement and the Demented Patient (Letter). Annals of
Internal Medicine 1986; 104: 582.
Non-Peer Reviewed: Published non-peer reviewed journal articles
Scholarly Books and Monographs:
Chapters in Scholarly Books and Monographs:
O’Rourke MA, Crawford J: Lung Cancer in the Elderly. Comprehensive Therapy 1988;
14(6):47-54.
O’Rourke MA, Cohen JH: Anemia in the Elderly. In Ham RH (Ed): Geriatric Medicine
Annual: 1987. Ordell, New Jersey, Medical Economics Book, 1987.
O’Rourke MA, Crawford J: Lung Cancer in the Elderly. Clinics in Geriatric Medicine,
1987; 3 (4): 595-624.
O’Rourke MA, Cohen JH: Multiple Myeloma in the Elderly. Medical Grand
Rounds,4(1):30-44,1986
Peer Reviewed Electronic Publications:
Non-Peer Reviewed Electronic Publications:
Other Publications: (e.g., newspapers and magazines)
O’Rourke, MA and Snyder, B. Who Will Speak for You When You are Unable? Greenville
News, April 16, 2012
O’Rourke, MA and Gluck, WL. Lifetime Clinic a Good Fit for Cancer Survivors, Greenville
News June 15, 2014